SCHEMBL3629291

SCHEMBL3629291

CCOC(=O)C1(CO)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.40
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
ADORA1 P30542 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TSHR P16473 1/20 0.33
HPGD P15428 1/20 0.33
EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25245654 0.89 SMN1; SMN2 (0.42) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL18728345 0.89 CYP4F2 (0.46) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL3634028 0.87 L3MBTL1 (0.40) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL22233140 0.87 ADORA1 (0.39) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL3634007 0.87 SMN1; SMN2 (0.37) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL21749176 0.86 L3MBTL1 (0.46) CYP4F2CYP4A11L3MBTL1MEN1KMT2A
SCHEMBL7309006 0.85 USP2 (0.43) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL23390562 0.84 NR1H2 (0.42) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2
SCHEMBL426525 0.83 SMN1; SMN2 (0.41) NR1H2SMN1; SMN2USP2ADORA1MEN1
SCHEMBL22233978 0.82 ALDH1A1 (0.34) NR1H2CYP4F2CYP4A11SMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-01-26 US disclosed
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-01-26 US disclosed
EP-4061124-A1 TRPV4 RECEPTOR LIGANDS University of Utah Research Foundation (US) 2022-09-28 EP disclosed
CN-115052478-A TRPV4 receptor ligands 犹他大学研究基金会 2022-09-13 CN disclosed
EP-3911644-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2021-11-24 EP disclosed
WO-2021102314-A1 TRPV4 RECEPTOR LIGANDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-05-27 WO disclosed
WO-2021102314-A1 TRPV4 RECEPTOR LIGANDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-05-27 WO disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 WO disclosed
EP-2155666-A1 AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS Pfizer Limited (GB) 2010-02-24 EP disclosed
WO-2008139287-A1 AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER LIMITED (GB) 2008-11-20 WO disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 NR1H2 4027/4885CYP4F2 4672/4885CYP4A11 4608/4885
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS TRPV4, TRPV2, TRPV3 NR1H2 231/4885CYP4F2 2169/4885CYP4A11 1142/4885
US-20080280877-A1 Azetidines PTGER2, PTGER1, PTGDR2 NR1H2 180/4885CYP4F2 1549/4885CYP4A11 771/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 NR1H2 4027/4885CYP4F2 4672/4885CYP4A11 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.